# Core C:  Uganda

> **NIH NIH P30** · CASE WESTERN RESERVE UNIVERSITY · 2022 · $479,262

## Abstract

PROJECT SUMMARY/ABSTRACT – UGANDA CORE C
The RUSTBELT CFAR Uganda Core C reached several impressive milestones: (i) The core was selected in 2017
as one of 2 lead National HIV drug resistance testing labs for genotyping second-line ART treatment failures. (ii)
We added next gen sequencing (NGS) to traditional Sanger-based sequencing for HIV drug resistance testing.
(iii) We achieved College of American Pathologists’ (CAP) accreditation in 2017 (recertified in 2019) for HIV drug
resistance testing. (iv) The EDITS assay to measure the HIV RNA reservoir was transferred from CWRU. (v)
Core C advanced HIV Cure, HIV-TB, HIV-associated malignancies, and cardiovascular complication projects.
(vi) Core C became a training and project site for Makerere University (MU) graduate students. The research
collaboration between MU and CWRU celebrated its 30th year in 2018 and is widely recognized as a model for
successful international cooperation and progress. Currently over 200 Ugandan scientists and health care
professionals are engaged in CFAR collaborative programs at the Joint Clinical Research Centre (JCRC), MU,
and Mulago Hospital in Kampala. Due to CFAR investments, cutting edge molecular HIV virology and clinical
immunology research in Uganda became possible. The integration of the University of Pittsburgh (Pitt) and
CWRU/UHMC to form the RUSTBELT CFAR significantly expands Core C’s research and training opportunities
for Ugandan, CWRU, and Pitt trainees and researchers by including a broader scope of translational, clinical,
and implementation research. Based on these milestones, Core C’s aims are (1) Provide virologic and
immunologic research support for studies on HIV complications and the role of gender on HIV infection in
Uganda. Core C will incorporate new innovative techniques and assays to study the role of gender in HIV
infection and its complications in the following studies: the impact of hormonal status and contraception on the
size of the HIV reservoir, the role of gender in HIV co-infection, cardiovascular complications of HIV, HIV
associated malignancies, and the microbiome in HIV patients. (2) Expand research on the impact of HIV drug
resistance on HIV prevention in Uganda. The collaboration with the team at Pitt brings on board a wealth of
expertise which will strengthen Core C in HIV drug resistance and HIV prevention research in Uganda. (3)
Provide support for new Translational HIV Research in Uganda for RUSTBELT CFAR investigators. Core C will
build on the clinical research experience in Uganda by CWRU’s TB Research Unit and the AIDS Clinical Trials
Unit. (4) Continue to provide biomedical training for Ugandan Master and PhD students. Core C through Fogarty
D43-010319 "Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda” (MITHU
(Boom, Karn, & Joloba, Co-PI). Integration of Pitt with the CWRU/UHMC CFAR to form the RUSTBELT CFAR
significantly expands Core C’s research and training opportunities in Uganda. Dr...

## Key facts

- **NIH application ID:** 10457724
- **Project number:** 2P30AI036219-26A1
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **Principal Investigator:** Immaculate Lillian Nankya
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $479,262
- **Award type:** 2
- **Project period:** 1997-04-01 → 2027-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10457724

## Citation

> US National Institutes of Health, RePORTER application 10457724, Core C:  Uganda (2P30AI036219-26A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10457724. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*